Searched for
TARIFF ON PHARMA
Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Why is market falling today? 7 triggers behind 800-point Sensex fall, Rs 4 lakh crore wealth wipeoutIndian stock markets experienced a decline on Wednesday as tensions in the Middle East escalated. Crude oil prices surged above $92 a barre...
- India's gem and jewellery exports rise 26.5% in June, shining at $2.21 billionIndia's gem and jewellery exports saw a significant rebound in June, increasing by 26.5 percent. Lower international gold prices and improv...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Hikal commissions cGMP pilot plant in Pune to strengthen pharmaceutical developmentHikal has commissioned an enhanced cGMP pilot plant at its Pune campus to strengthen its integrated capabilities for pharmaceutical develop...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- Parliament Watch: FM on rupee, `16.1 lakh cr fuel taxes, India-US trade talks and moreRupee depreciation is influenced by rising crude oil prices and reduced capital account support. India monitors US trade policy changes and...
- India engaged with the US, studying all the developments: Govt tells ParliamentThe government told Parliament it is closely monitoring developments in its trade relationship with the US and remains engaged with Washing...
- Pharma exports to UK may rise up to 10% in FY27 as CETA takes effectIndia's pharmaceutical exports to the UK are set to witness substantial growth thanks to the recently negotiated Comprehensive Economic and...
- India-UK FTA projected to boost Indian pharma exports by over 8% to $981 million in FY27: PharmexcilIndian pharmaceutical exports to the United Kingdom are projected to grow significantly. The India-UK Comprehensive Economic and Trade Agre...
- Index returns likely to be slightly above long-term averages over next 2 years: Mirae Asset CIO Neelesh Surana on market outlook, fund strategiesMirae Asset Investment Managers (India)’s equity funds have experienced a period of underperformance—the first major blip since inception i...
- Stocks, gold and debt: Why ICICI Pru’s Dharmesh Kakkad favours a multi-asset strategy nowICICI Prudential's Dharmesh Kakkad advises investors against chasing the best-performing asset classes, arguing that a dynamic multi-asset ...
- India-UK FTA: Pharma industry flags regulatory priorities ahead of July 15 rolloutIndustry stakeholders expect stronger trade, investment, and research partnerships but say implementation clarity will determine the pact’s...
- Cost pressure to keep Q1 profit growth muted for Nifty 50 companiesNifty 50 companies anticipate double-digit revenue growth for the June 2026 quarter. Profit growth is projected to remain in single digits ...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities ended lower after four straight gains as profit booking, weak global cues and caution ahead of the US Fed minutes weighed o...
Load More
